Press Releases
- Aug 11, 2016- Q2 marked by positive, confirmatory proof-of-concept results in large-animal studies of proprietary Cellspan™ technology and manuscript with Mayo Clinic being finalized for publication
Biostage, Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the...
- Jul 28, 2016
Biostage, Inc. (NASDAQ: BSTG) a biotechnology company developing bioengineered organ implants for life-threatening conditions of the esophagus, trachea and bronchus, will host a conference call on...
- Jul 21, 2016
Biostage, Inc. (Nasdaq: BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea,...
- Jun 29, 2016Orphan Drug Designation Provides Range of Benefits Including Seven-Year Market Exclusivity
Biostage, Inc. (Nasdaq: BSTG), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, today...
- Jun 21, 2016Overview Notes Continued Progress with Organ Regeneration Program
Biostage, Inc. (NASDAQ: BSTG), a biotechnology company developing bioengineered organ implants to treat cancer and other life-threatening conditions of the esophagus, bronchus and trachea, today...
